The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.
 
E. Antonio Chiocca
Stock and Other Ownership Interests - DNAtrix; Immunomic Therapeutics; Seneca Therapeutics
Honoraria - GlaxoSmithKline; Merck
Consulting or Advisory Role - Advantagene; DNAtrix; InSightec; Merck; Sangamo Therapeutics; Voyager Therapeutics
Research Funding - Amgen; Newlink Genetics
Patents, Royalties, Other Intellectual Property - Patents related to oncolytic virus technology, gene therapy, microRNA, exosome, antibodies
 
Isaac Solomon
No Relationships to Disclose
 
Hiroshi Nakashima
No Relationships to Disclose
 
Sean Edward Lawler
Research Funding - Chimerix
Patents, Royalties, Other Intellectual Property - Candel Therapeutics
 
Daniel Triggs
No Relationships to Disclose
 
Abigail Zhang
No Relationships to Disclose
 
James Grant
No Relationships to Disclose
 
David A. Reardon
Honoraria - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; DelMar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Omniox
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Prime Oncology
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Keith L. Ligon
Stock and Other Ownership Interests - Travera
Consulting or Advisory Role - Bristol-Myers Squibb; BroadBranch Consulting; Integragen; RareCyte
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Plexxikon (Inst); Tragara (Inst); X4 Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Molecular Diagnostics Assay Patent
Expert Testimony - Crico
 
William Pisano
No Relationships to Disclose
 
Scott J. Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Mario Suva
Stock and Other Ownership Interests - Immunitas
Consulting or Advisory Role - Immunitas
 
Kai Wucherpfennig
Employment - Brookline Dental Center (I)
Stock and Other Ownership Interests - TCR2 Therapeutics
Consulting or Advisory Role - Immunitas; Nextech Invest; SQZ Biotech; TCR2 Therapeutics; TScan Therapeutics
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Immunitas
 
Simon Gritsch
No Relationships to Disclose
 
Nathan D. Mathewson
Consulting or Advisory Role - Immunitas
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent awarded: PCT/US2018/060857 Methods and Compositions for Treating Cancer by Targeting the CLEC2D-KLRB1 Pathway 11/2018; Patent pending: US 62/925,663 Monoclonal Antibodies that Bind Human CD161 and Uses Thereof 11/2019
 
David Krisky
Employment - Candel Therapeutics
Leadership - Periphagen
Stock and Other Ownership Interests - Candel Therapeutics
Consulting or Advisory Role - Diamyd Medical
Patents, Royalties, Other Intellectual Property - Periphagen
 
Estuardo Aguilar-Cordova
Employment - Candel Therapeutics
Leadership - Candel Therapeutics
Stock and Other Ownership Interests - Candel Therapeutics
Patents, Royalties, Other Intellectual Property - Candel Therapeutics
 
Laura K. Aguilar
Employment - Candel Therapeutics
Leadership - Candel Therapeutics
Stock and Other Ownership Interests - Candel Therapeutics
Patents, Royalties, Other Intellectual Property - Candel Therapeutics